LEADER 02315nam  2200613Ia 450 
001 9910465666103321
005 20200520144314.0
010   $a1-282-91702-1
010   $a9786612917028
010   $a0-309-15333-6
035   $a(CKB)2560000000069604
035   $a(SSID)ssj0000443504
035   $a(PQKBManifestationID)11299723
035   $a(PQKBTitleCode)TC0000443504
035   $a(PQKBWorkID)10456032
035   $a(PQKB)11314061
035   $a(MiAaPQ)EBC3378704
035   $a(Au-PeEL)EBL3378704
035   $a(CaPaEBR)ebr10433659
035   $a(CaONFJC)MIL291702
035   $a(OCoLC)703252903
035   $a(EXLCZ)992560000000069604
100   $a20100826d2010      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aTransforming clinical research in the United States$b[electronic resource] $echallenges and opportunities : workshop summary /$fRebecca A. English, Yeanwoo Lebovitz, and Robert B. Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
210   $aWashington, D.C. $cNational Academies Press$dc2010
215   $axvii, 131 p. $cill. (some col.), col. maps
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-309-15332-8 
320   $aIncludes bibliographical references (p. 103-105).
606   $aClinical trials$zUnited States$vCongresses
606   $aClinical trials$xResearch$zUnited States$vCongresses
606   $aClinical trials$xGovernment policy$zUnited States$vCongresses
608   $aElectronic books.
615  0$aClinical trials
615  0$aClinical trials$xResearch
615  0$aClinical trials$xGovernment policy
676   $a610.72/4
701   $aEnglish$b Rebecca A$0897032
701   $aLebovitz$b Yeonwoo$0936149
701   $aGiffin$b Robert B$0906709
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
712 02$aNational Academies Press (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910465666103321
996   $aTransforming clinical research in the United States$92108868
997   $aUNINA